Nivolumab,Ipilimumab,177Lu-PSMA-617
BMS,Novartis
['psma-617 ', 'crpc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'nivo', 'ipi/', 'gu ']
gu asco 23: pca trials in progress
evolution: phase ii lu-psma-617 +ipi/nivo versus lu-psma-617 in mcrpc progressed on prior arat (prior doce allowed):
-primary endpoint: 12 mo psa-pfs
-secondary endpoints: os, rpfs, orr, hrqol
-51/100 recruited--&gt;comp: dec 24
#gu23 
MD, MSc | @UofTUrology @SUO_YUO Fellow & @IHPMEUofT CEHCR PhD| Previously: @AUB_Lebanon and @MCG_Urology